29.03.2010 • NewsGlaxoSmithKline (GSK)Japan

Glaxo Seeks Out Japanese Partnerships

GlaxoSmithKline is looking to join up with small and medium-sized companies in Japan to help it develop and distribute new medicines, the Financial Times reported in its Monday edition. Glaxo's Asia-Pacific head Marc Dunoyer said the British drugs firm was looking to work with and invest in firms but would not take a controlling stake.

"The medium-sized segment of Japan is where we're going to focus our attention," Dunoyer was cited as saying in the FT. "It's about reassuring them that we're not going to take them out, but that we have some complementary areas," Dunoyer said.

Glaxo is eyeing new opportunities in Japan, where a raft of medicines that are already well established in home markets are winning approval and being launched. Emerging markets, with nine-month sales of £2.1 billion and year-on-year growth of 19%, currently make up 13% of Glaxo group sales. Japan accounts for some 4%.

Interview

Stability in Motion
Strategic Response to a Shifting Pharma Landscape

Stability in Motion

Stefan Oelrich, Member of the Board of Management and President Pharmaceuticals, Bayer, discusses navigating external volatility, reshaping its internal structures, and investing in future-ready capabilities to ensure sustainable growth.

Free Expert Insights

Dual‑Targeting Breakthroughs
Advancements in Bispecific Antibody Development

Dual‑Targeting Breakthroughs

Unlock the latest breakthroughs in bispecific antibody development! Download Wiley’s free Expert Insights eBook to explore cutting-edge dual-targeting strategies, advanced purification methods, and bioanalytical technologies transforming immunotherapy and cancer treatment.

most read

Photo
28.07.2025 • NewsChemistry

VCI Welcomes US-EU Customs Deal

The German Chemical Industry Association (VCI) welcomes the fact that Ursula von der Leyen, President of the European Commission, and US President Donald Trump have averted the danger of a trade war for the time being.